SAB Biotherapeutics (NASDAQ:SABS) Price Target Raised to $25.00 at Chardan Capital

SAB Biotherapeutics (NASDAQ:SABSFree Report) had its price objective raised by Chardan Capital from $3.00 to $25.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright cut their target price on shares of SAB Biotherapeutics from $10.00 to $6.00 and set a buy rating on the stock in a research note on Tuesday.

Read Our Latest Research Report on SAB Biotherapeutics

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $4.50 on Tuesday. SAB Biotherapeutics has a 52-week low of $3.66 and a 52-week high of $14.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.34 and a current ratio of 0.34. The stock’s 50 day moving average price is $5.24 and its two-hundred day moving average price is $2.84.

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SABS. RTW Investments LP acquired a new position in SAB Biotherapeutics during the 4th quarter valued at about $6,310,000. BVF Inc. IL bought a new position in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $6,310,000. Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $1,259,000. Vanguard Group Inc. lifted its holdings in SAB Biotherapeutics by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 996,132 shares of the company’s stock worth $685,000 after acquiring an additional 19,194 shares during the period. Finally, Pathstone Family Office LLC bought a new stake in SAB Biotherapeutics during the third quarter worth $319,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

Featured Articles

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with's FREE daily email newsletter.